Navin Fluorine International Ltd Q1 FY2023 Concall Summary

Key Takeaways

• Strong quarter, broad-based growth: Revenue rose 23% YoY to Rs. 386.8 crore, with EBITDA margin expanding 100 bps to 25.8%, driven by record Specialty Chemicals performance and robust HPP volumes.
• Honeywell plant inaugurated and stabilized ahead of schedule: The complex Dahej facility was completed through three COVID-19 waves, and the first HPP plant stabilized in under four weeks versus a 3-6 month expectation, with trial supplies from the second plant already underway.
• CDMO faces a soft H1 but a visibly strong H2: Revenue dipped YoY this quarter, and management flagged that Q2 will not close the gap, but the pipeline for H2 and calendar year 2023 is described as extremely strong, supported by a new order from a large US-based company post-audit.
• New organizational structure signals a growth-focused phase: The company split into three P&L-led BUs (HPP, CDMO, Specialty Chemicals), appointed a CEO for HPP, and is actively investing in R&D, debottlenecking, and new business development hires in the US and Europe.
• What to watch next quarter: The pace of CDMO's H2 ramp-up as new orders convert, revenue contribution from the Honeywell plant, and any strategic decisions on new emerging segments and the cGMP4 business case.

Business Performance & Drivers

• Specialty Chemicals delivered a record quarter: Revenue of Rs. 176 crore, up 32% YoY, was driven primarily by higher volumes of existing molecules and one new molecule launch, with margin improvement coming from a favorable product mix.
• HPP growth was powered by both volume and pricing: Revenue grew 33% YoY to Rs. 152 crore, with Refrigerant Gas growth more volume-driven across domestic MSM, non-MSM, and international segments, while Inorganic growth was more pricing-driven alongside strong volumes.
• CDMO revenue softened as a transitional pause: Revenue of Rs. 59 crore was down from Rs. 67 crore in Q1 FY22, but management cautioned against a quarterly read, emphasizing that H2 is expected to be extremely strong and that the softness is not due to issues in Europe.
• Gross margin improved sequentially by 220 bps: The expansion was attributed to a mix of price increases and a favorable product mix shift, particularly toward higher-margin molecules in the Inorganic segment.
• HPP plant stabilization was a standout operational win: The technology supplier expected the first plant to take 3-6 months to stabilize; the internal team achieved this in less than four weeks, and trial quantities from the second plant are already being supplied.

Welling: "Our team has actually managed to stabilize that plant in less than four weeks. We've already started supplying the trial quantities from the second plant. So, I think our initial experience has been extremely heartening. What our technology supplier expected us to do in three to six months, the team has really achieved in the record time."

Strategic Reorganization & Business Configuration

• Three distinct BUs were created with full P&L accountability: The new structure separates HPP, CDMO, and Specialty Chemicals, each headed by an operating CEO, to sharpen strategic focus and execution as the businesses have fundamentally different models.
• The business models are deliberately distinct: Management framed Specialty as a service business, CDMO as a service-plus-product business, and HPP as a product business, a configuration that shapes how each unit is managed and measured.
• Segment combination was a deliberate confidentiality move: Inorganic, Refrigerant Gas, and HPP were grouped together partly because some are single or limited-molecule businesses, and separate disclosure would make it easy for competitors to reverse-engineer molecule-level revenue.
• Mr. Partha Roychowdhury was appointed CEO of HPP: A former Navin executive who served as CFO from 1995 to 2016, his appointment brings deep institutional knowledge to a business entering a scaling phase.

Welling: "And the third reason is that some of these businesses are almost like single molecule or limited molecule businesses. So, when we actually declare the results of some of these businesses separately, it's very easy for the competition to really understand what the revenue is of that one specific molecule or those limited number of molecules. And for confidentiality reasons, we didn't want all of that to be so transparent."

CDMO: Soft Patch Now, Strong Pipeline Ahead

• H1 softness is acknowledged and H2 is expected to more than compensate: Management stated that Q2 will not take care of the gap in the run rate, but the business pipeline for calendar year 2023 is looking extremely strong, and the full-year growth story remains intact.
• A milestone US customer audit was cleared successfully: The company completed an important plant audit for a large US-based company and has already received its first order from them, a tangible lead indicator for the H2 ramp-up.
• Europe is seen as a net mid-to-long-term positive: While issues in Europe will impact the CDMO side in the near term, the company is accelerating its move into advanced intermediates to mitigate this and positioning itself as an alternative manufacturing base, a dialogue also happening on the agrochemical side.
• The customer base is concentrated among top biopharma: A significant portion of CDMO revenue comes from top 20 biopharma companies, and smaller biopharma firms' molecules have often been acquired by these large players, keeping the customer profile consistently large-institution.
• New BD hires in the US and Europe aim to diversify the pipeline: The focus is on bringing in new biopharma customers from both US coasts, deepening engagement with existing customers, and generating more inquiries including non-fluoro opportunities.

Welling: "We believe that the issues that we are seeing in Europe will clearly have impact on two businesses. We are trying to understand what the potential impact could be on the HPP side both from the opportunity perspective as well as challenge perspective, but we clearly understand that it will have an impact on the CDMO side, which is why we are accelerating our move into at least the advanced intermediate" [15-16]

Capex, Capacity & Project Pipeline

• The Honeywell plant is moving from trial to commercial supply: Inaugurated on July 12, the Dahej facility produces a next-generation product with very low GWP and no ozone depletion potential, with revenue starting in Q2 FY23.
• Multiple capacity expansions are on a defined timeline: The cGMP3 expansion is scheduled for completion in Q3 FY23, the dedicated agrochemical facility by December 2022, MPP commissioning in stages from Q2 onwards, and a final building-block project by December 2023.
• An Rs. 80 crore HPP debottlenecking was approved: The capex is for a new molecule at the Surat HPP unit, with manufacturing expected to start from July 2023, though the specific molecule was not disclosed as raw material locking is still in progress.
• The cGMP4 business case is being prepared for approval: Management has started working on cGMP4 and expects the business case to be taken for approval soon, driven by a strong business pipeline.
• Existing plants are running at high utilization: The Surat HPP plant is at almost full capacity, and Specialty multi-purpose plants are also near full capacity with some product-by-product variation, while the Refrigerant Gas plant has headroom.
• R&D investment is being scaled up meaningfully: A large infrastructure upgradation project is underway at Surat for R&D and pilot plants, with 10-15% of profits directed into R&D and 10 new products slated for commercialization in FY23.

Strategic Outlook & Long-Term Ambition

• The ambition is to be significantly bigger and qualitatively different by FY25/26: Management stated that if announced projects are executed well, the company will be significantly larger than in FY22, with a different nature and quality of business driven by a momentum effect from successful execution.
• The performance material space is a large, targeted adjacency: The company plans to apply its existing capabilities, building blocks, and platforms from agrochemical and pharma into the performance material space, which management described as significantly larger.
• Share of wallet with large customers is still minimal: Management noted that with large customers, the company has just started scratching the surface, and its share of wallet remains a very small percentage of their total purchase basket, implying a long runway.
• New emerging segments are being evaluated for future investment: Opportunities have been identified both within HPP and outside it in new emerging segments that are non-incremental in nature, with a decision on their organizational home expected soon.
• The capability gap versus new entrants must be actively maintained: Management emphasized that continuously upgrading fluorination capabilities across chemistry, engineering, infrastructure, and talent is critical to ensuring the gap with new players persists.

Welling: "our clear focus is to ensure that if you look at by, let's say FY25 or FY26, in terms of size, we would be significantly bigger than what we were in FY22. Also, the nature and the quality of business will be significantly different than what has been in the past or what it was in FY22."

Margins & Capital Allocation

• EBITDA margin expanded 100 bps YoY to 25.8%: The improvement came despite input cost headwinds, with management pointing to pricing power and a favorable product mix as the key drivers.
• The HPP contract structure provides margin visibility: The agreement with the HPP partner was structured on a cost-plus basis, so increases in input costs have a clear pass-through mechanism, though some lag effects are possible.
• Working capital is expected to remain around 90 days: Management guided that this level should hold, with only minor short-term variations likely.
• Specialty will likely take a large portion of near-term capex: All three businesses have growth plans, but Specialty is expected to absorb a significant share of overall capital allocation, alongside cGMP4 for CDMO and other HPP opportunities.

Guidance & Commitments

Key Metrics